TOVX
Theriva Biologics·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 0
Bearish signal 1
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TOVX
Theriva Biologics, Inc.
A diversified clinical-stage company that developing therapeutics for cancer
9605 Medical Center Drive, Ste. 270, Rockville, MD 20850
--
Founded in 1986, Theriva Biologics, Inc., is a biotechnology company focused on the development of synthetic DNA-based therapies and innovative disease-mitigating drugs for the treatment of serious diseases. The company is a diversified clinical-stage company developing therapies designed to treat diseases in areas of high unmet need. The company entered the field of oncology through the acquisition of VCN Biosciences, VCN Biosciences, SL developed a new oncolytic adenovirus platform designed for intravenous, intravitreal and anti-tumor delivery to trigger tumor cell death, improve tumor access by co-administered cancer therapies, and promote a strong and sustained anti-tumor response from the patient's immune system.
Company Financials
EPS
TOVX has released its 2025 Q3 earnings. EPS was reported at -0.45, versus the expected -0.38, missing expectations. The chart below visualizes how TOVX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
